Skip to content

Evaluation of efficiency and acceptance of Self-Assembling Peptide Matrix (Oligo-Peptide 103 technology) application on hypersensitive MIH teeth – a prospective clinical study

Evaluation of efficiency and acceptance of Self-Assembling Peptide Matrix (Oligo-Peptide 103 technology) application on hypersensitive MIH teeth – a prospective clinical study - MIHpeptid

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00039501
Enrollment
25
Registered
2026-03-30
Start date
2026-02-20
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MIH hypersensitivity K00-K14

Interventions

Group 1: In-office application of Self-Assembling Peptide Matrix (Curodont™ Repair, vVardis, Switzerland) combined with daily home use of a Self-Assembling Peptide Matrix gel (Curodont™ Protect, vVar

Sponsors

ZZMK/ Poliklinik für Kinderzahnheilkunde
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 17 Years

Inclusion criteria

Inclusion criteria: - Hypersensitive MIH tooth (MIH-TNI 3 & 4a/b/c as well as SCASS 2 or 3) - Children (= 6 years) & adolescents without systematic health diseases with agreement to voluntary study participation. - A signed Informed consent from the caregiver or the patient for the study participation. - No sealing therapy or in office application of desensitizing agent on the MIH-teeth within 1 month before participation in the study. - Willing to apply once daily before going to bed a sufficient layer of Curodont Protect (VVARDIS, Switzerland) - Willing to come back after 12 weeks for Recall and reassessment

Exclusion criteria

Exclusion criteria: - Patients with acute pain / irreversible pulpitis or symptoms to be treated. - Patients with systemic disease that require special attention during their dental treatment. - Parents / children who refused to participate in the study. - MIH teeth with signs of irreversible pulpitis. - Allergy against any ingredients of the material (Curodont Repair + Protect, VVARDIS, Switzerland).

Design outcomes

Primary

MeasureTime frame
Degree of hypersensitivity after in office application of Self-Assembling Peptide Matrix (Curodont™ Repair, vVardis, Switzerland) in the same visit (15 minutes after the application) and after daily home use of Self-Assembling Peptide Matrix gel (Curodont™ Protect, vVardis, Switzerland) for 3 months according to Schiff Cold Air Sensitivity (SCASS) Test and the self-report of the child using Wong Baker Faces Rating Scale (WBFS)

Secondary

MeasureTime frame
- Change in the degree of hypersensitivity in the treated MIH teeth according to parental assessment. - Assessment of acceptance of the child toward the application of the material at home using Likert Scale. - Assessment of cooperation of the child during the application using Frankl behaviour rating scale. - Evaluation of the taste acceptance of Self-Assembling Peptide Matrix (Curodont Repair + Protect, VVARDIS, Switzerland) in the child and their preference regarding the taste of the material. - Satisfaction of the patient, caregiver and operating dentist.

Countries

Germany

Contacts

Public ContactJulian Schmoeckel

ZZMK/ Poliklinik für Kinderzahnheilkunde

julian.schmoeckel@uni-greifswald.de+49 (0) 3834/ 867136

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026